Cargando…

Transgenic expression of IL-7 regulates CAR-T cell metabolism and enhances in vivo persistence against tumor cells

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising novel therapeutic approach. However, primary and secondary resistance to CAR-T cell therapy is commonly encountered in various clinical trials. Despite the comprehensive studies to elucidate the mechanisms of resistance, effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Li, Li, Qing, Yan, Zi-Xun, Sheng, Ling-Shuang, Fu, Di, Xu, Pengpeng, Wang, Li, Zhao, Wei-Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307822/ https://www.ncbi.nlm.nih.gov/pubmed/35869100 http://dx.doi.org/10.1038/s41598-022-16616-2

Ejemplares similares

Analysis of causes for poor persistence of CAR-T cell therapy in vivo
por: Kong, Yingjie, et al.
Publicado: (2023)

IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation
por: Battram, Anthony M., et al.
Publicado: (2021)

Engineered IL-7 Receptor Enhances the Therapeutic Effect of AXL-CAR-T Cells on Triple-Negative Breast Cancer
por: Zhao, Zhenhui, et al.
Publicado: (2020)

IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells
por: Hombach, Andreas A., et al.
Publicado: (2020)

Improving CAR T-Cell Persistence
por: Pietrobon, Violena, et al.
Publicado: (2021)

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
por: Kim, Miriam Y., et al.
Publicado: (2022)

IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
por: Pang, Nengzhi, et al.
Publicado: (2021)

IL-24 armored CAR19-T cells show enhanced antitumor activity and persistence
por: Hu, Qian, et al.
Publicado: (2021)

IL-7 Promotes the Transition of CD4 Effectors to Persistent Memory Cells
por: Li, JiChu, et al.
Publicado: (2003)

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy
por: Xin, Tianqing, et al.
Publicado: (2022)

Potential strategies against resistance to CAR T-cell therapy in haematological malignancies
por: Cai, Qing, et al.
Publicado: (2020)

Biomaterials promote in vivo generation and immunotherapy of CAR-T cells
por: Qin, Ya-Ting, et al.
Publicado: (2023)

IL-7 and CCR2b Co-Expression-Mediated Enhanced CAR-T Survival and Infiltration in Solid Tumors
por: Li, Guangchao, et al.
Publicado: (2021)

IL-21 Optimizes the CAR-T Cell Preparation Through Improving Lentivirus Mediated Transfection Efficiency of T Cells and Enhancing CAR-T Cell Cytotoxic Activities
por: Du, Li, et al.
Publicado: (2021)

Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
por: Song, Yanjing, et al.
Publicado: (2017)

Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors
por: Li, Fanfan, et al.
Publicado: (2022)

B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer
por: Li, Shibao, et al.
Publicado: (2023)

Lenalidomide Enhances CAR-T Cell Activity Against Solid Tumor Cells
por: Wang, Zhixiong, et al.
Publicado: (2020)

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma
por: Gargett, Tessa, et al.
Publicado: (2022)

Chimeric antigen receptor T (CAR-T) cells expanded with IL-7/IL-15 mediate superior antitumor effects
por: Zhou, Jianxia, et al.
Publicado: (2019)

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
por: Shiqi, Li, et al.
Publicado: (2023)

B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo
por: Zhang, Qian, et al.
Publicado: (2022)

CAR-T Cell Performance: How to Improve Their Persistence?
por: López-Cantillo, Gina, et al.
Publicado: (2022)

Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo
por: Yin, Yuzhen, et al.
Publicado: (2022)

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
por: Wang, Hongxia, et al.
Publicado: (2021)

MDA-7/IL-24 functions as a tumor suppressor gene in vivo in transgenic mouse models of breast cancer
por: Menezes, Mitchell E., et al.
Publicado: (2015)

Promoter usage regulating the surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo
por: Ho, Jin-Yuan, et al.
Publicado: (2021)

Enhancing T cell persistence of CAR-redirected T cells in solid tumors
por: Guedan, Sonia, et al.
Publicado: (2014)

T cell senescence and CAR-T cell exhaustion in hematological malignancies
por: Kasakovski, Dimitri, et al.
Publicado: (2018)

PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies
por: Jie, Yamin, et al.
Publicado: (2021)

The effect of in vivo IL-7 deprivation on T cell maturation
Publicado: (1995)

Successful application of anti-CD19 CAR-T therapy with IL-6 knocking down to patients with central nervous system B-cell acute lymphocytic leukemia
por: Chen, Li-Yun, et al.
Publicado: (2020)

IL7 and IL7 Flt3L co-expressing CAR T cells improve therapeutic efficacy in mouse EGFRvIII heterogeneous glioblastoma
por: Swan, Sheridan L., et al.
Publicado: (2023)

Molecular cloning of chicken IL-7 and characterization of its antiviral activity against IBDV in vivo
por: Huo, Shanshan, et al.
Publicado: (2016)

Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors
por: Zhang, Gui-Zhen, et al.
Publicado: (2019)

Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice
por: Li, He, et al.
Publicado: (2018)

IL-2 Restores T-Cell Dysfunction Induced by Persistent Mycobacterium tuberculosis Antigen Stimulation
por: Liu, Xun, et al.
Publicado: (2019)

Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy
por: Xing, Limin, et al.
Publicado: (2021)

Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion
por: He, Cong, et al.
Publicado: (2020)

Synergistic effect of ibrutinib and CD19 CAR‐T cells on Raji cells in vivo and in vitro
por: Liu, Meijing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nkfomdhe4ndkv2foms472kol66